INTRODUCTION
Landmark studies have shown that the vascular endothelial growth factor-specific (VEGF) monoclonal antibodies bevacizumab and ranibizumab are currently the best treatments for patients with age-related macular degeneration (AMD) and subfoveal choroidal neovascularization (CNV) (1) (2) (3) (4) (5) (6) . Except for a single case report, the studies reported on patients whose neovascularization extended beneath the center of the foveal avascular zone (7) . The Macular Photocoagulation Studies showed that laser photocoagulation was effective in reducing vision loss in patients with extrafoveal CNV (≥200 µm from the foveal center) and juxtafoveal CNV µm from the foveal center), but the effect was limited to eyes with classic CNV lesions (8) (9) (10) (11) . Problems with thermal laser treatment include damage to the fovea and a high recurrence rate of CNV after treatment. Thermal laser treatment can however potentially eradicate CNV, preventing the need for repeated injections of a VEGF inhibitor. Evidence for the use of PDT for the treatment of extrafoveal and juxtafoveal CNV associated with AMD has also been published, but is limited and has had highly variable results (12) (13) (14) (15) . AMD patients with non-subfoveal CNV need prompt treatment to avoid macular damage from fluid, hemorrhage, or scar- ring from extension of the CNV into the fovea. Anti-VEGF therapy offers the promise of effectively treating the neovascular process while causing less damage than thermal laser. Herein we present data from a series of patients with AMD and vision loss from CNV that did not extend beneath the fovea who were treated with bevacizumab and/or ranibizumab. We compare these results with those from the Macular Photocoagulation Studies.
METHODS
This study was approved by the Human Subjects Review Committee of The University of Iowa Hospitals and Clinics. Patients were collected from the practice of Dr. James Folk at The University of Iowa. Every patient under active treatment with either bevacizumab or ranibizumab for neovascular AMD during the consecutive two month period from May 2008 to June 2008 was potentially eligible. A retrospective chart review was performed for all included patients. Fundus fluorescein angiography (FFA) obtained at the time of initial presentation was reviewed to confirm the diagnosis of AMD and to determine if the choroidal neovascularization extended beneath the center of the fovea. Inclusion criteria included neovascularization within the macula that did not extend beneath the center of the foveal avascular zone (FAZ), along with at least one large drusen (≥125 µ) or many intermediate size (63-124 µ) drusen. Specific exclusion criteria included: geographic atrophy of the RPE that involved the fovea, fundus changes compatible with myopic degeneration, angioid streaks, chorioretinal scars in the macula which could indicate choroidal inflammatory disease, or history of any previous treatment for CNV or any other retinal disease in the treatment eye.
The distance of the closest point of either the occult or classic neovascularization to the center of the FAZ was measured in microns using software on the digital photographic system. In general a mid-phase image of the angiogram was used when the neovascularization was completely filled but had not yet leaked sufficiently to obscure its margins. Using criteria from the MPS, choroidal neovascularization was considered to be extrafoveal if its closest point did not extend closer than 200 µ to the center of the FAZ, and was classified as juxtafoveal if the closest point was closer than 200 µ to the center but did not extend under the center of the FAZ. The determination of whether the neovascularization was predominantly classic or occult was made using previously reported criteria (12) . Patients were examined at 4-8 week intervals. At each visit, best corrected Snellen visual acuity was measured and Stratus optical coherence tomography (OCT) was performed and evaluated for the presence of intraretinal or subretinal fluid. The central macular thickness as determined by OCT was recorded. Repeat injections were performed until no subretinal or intraretinal fluid was seen on the OCT, at which time they were considered an "anatomic success." Two of the thirteen patients were not followed with OCT imaging but instead by their symptoms, visual acuity, and careful examination of the macula. Per our customary practice to prevent recurrence, all patients were treated with additional injections even after they exhibited resolution of subretinal fluid but the treatment interval was gradually extended to up to 6 months. All patients had at least 6 months of follow-up since diagnosis, and the mean total follow-up time was 9.6 months.
RESULTS
The review resulted in 13 patients who met the criteria, none of whom were excluded. Mean patient age was 81 (±6.8) years (Table 1) . Seven patients had classic lesions, three had occult and three predominately occult CNV. Of the 13 patients, nine (69%), had extrafoveal CNVand four, (31%), had juxtafoveal CNV.
Seven patients were initially treated with an intravitreal injection of 1.25 mg bevacizumab and six were treated initially with 0.5mg of ranibizumab. Two of the thirteen patients received both agents at different points over the course of their treatment. Mean visual acuity at the time of diagnosis was 20/60 (logMAR 0.5, ± 0.28). Follow-up ranged from 6-24 months (Mean=9.6). The results were determined from data collected at the last visit. The total number of injections averaged 5 (±2.6). Eleven patients had reduction of retinal thickening in the area involved by the CNV and the average central macular thickness reduction after treatment was 78 ± 69 microns. The other two patients who did not have OCT data had no fluid or activity on clinical examination. No patient had increased central macular thickness on OCT as of the last follow-up.
At the final follow-up visit, one patient (8%) had lost one line of vision since the beginning of treatment; one (8%) had remained stable, and eleven (84%) had gained one or more lines of visual acuity ( Table 2 ). Three patients (23%) gained three or more lines. The average treatment outcome for all patients was a gain of 1.7 ± 1.3 lines of Snellen acuity (Table 1, 2). Both therapeutic agents were effective, with an average gain of 1.6 ± 0.6 lines for patients treated with bevacizumab, 1.5 ± 1.9 lines gained for patients treated with ranibizumab and 2.5 ± 0.7 lines gained in the two patients who received both agents over the course of their treatment. This study was too small to calculate statistically significant differences in treatment outcomes between the extrafoveal and juxtafoveal groups, the different CNV lesion types, or between the therapeutic agent used. However, results in all subgroups appeared One line of visual acuity assumed as equivalent to five ETDRS letters for purpose of study comparison; *= data from 0.5 mg ranibizumab treatment group similarly favorable. All of the 13 patients responded to treatment evident by resolution of retinal or subretinal edema on OCT, visual improvement or clinical resolution of hemorrhage and edema associated with CNV.
DISCUSSION
The results of this small series of nonsubfoveal CNV in patients with AMD are similar to the visual results of the large MARINA and ANCHOR trials for subfoveal CNV ( Table 3) . As demonstrated in these trials, both occult and classic neovascularization responded to anti-VEGF therapy in our patients. A slightly greater proportion of our patients had 20/40 or better acuity, probably because there was no subfoveal scarring. We also attempted to compare our results with the MPS studies which used argon laser to treat extrafoveal CNV and krypton red laser to treat juxtafoveal CNV (Table 4 ). While our results seem favorable, a comparison of different patient groups from different studies and different decades is impossible to interpret in a scientific manner. A prospective, randomized controlled trial is needed to confirm our results.
Bevacizumab and/or ranibizumab was successful at controlling the CNV in all of our study patients. Only one of the 13 patients in this study lost one line of vision, one remained stable, 
